NC
APGE

nVerses Capital’s Apogee Therapeutics APGE Stock Holding History

nVerses Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100
Closed -$6.64K – 995
2024
Q1 		$6.64K Buy
+100
New +$4.37K 0.02% 544

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

nVerses Capital's APGE Position: Q2 2024 in Review

nVerses Capital sold out of Apogee Therapeutics (APGE) in Q2 2024, closing a stake of 100 shares — an estimated $6.64K sold.

nVerses Capital first reported a position in APGE in Q1 2024 and held it in 1 quarter. The position peaked at $6.64K in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q2 2024.

  • nVerses Capital reported no remaining Apogee Therapeutics position as of Q2 2024 after selling out during the quarter.
  • nVerses Capital sold 100 Apogee Therapeutics shares in Q2 2024, an estimated $6.64K.
  • nVerses Capital first reported a position in Apogee Therapeutics in Q1 2024 and held it in 1 quarter.
  • nVerses Capital's Apogee Therapeutics position peaked at $6.64K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2024.

Based on nVerses Capital's 13F filing for Q2 2024, filed 31 Jul 2024.